Literature DB >> 22172356

Long-term physiological consequences of pneumonectomy.

Jean Deslauriers1, Paula Ugalde, Santiago Miro, Deborah R Deslauriers, Sylvie Ferland, Sébastien Bergeron, Yves Lacasse, Steeve Provencher.   

Abstract

Ever since the first successful pneumonectomy for lung cancer was performed in 1933, a number of largely historical reports have attempted to look at the physiological consequences of this operation in order to define patient long-term functional status. The pertinence of these contributions is, however, limited because most were performed in patients who had their pneumonectomy for benign diseases or were carried out in small and heterogeneous populations. Thus, several surgical myths and beliefs such as phrenic nerve interruption at the time of operation might be desirable, marked hyperinflation of the residual lung is associated with reduced lung function, and patients develop pulmonary hypertension over time and have poor exercise tolerance have persisted over the years. Our findings based on a study of 100 patients evaluated 5 or more years after surgery (mean follow-up time, 9.1 ± 2.8 years [5.0-14.7 years]) show that most patients can adjust to living with only one lung and are thus able to live a near-normal life. Although diaphragmatic paralysis is characterized by significant alterations in respiratory function, hyperinflation of the residual lung is beneficial.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22172356     DOI: 10.1053/j.semtcvs.2011.10.008

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  9 in total

1.  The nexus of functional exercise capacity with health-related quality of life in lung cancer: how closely are they related?

Authors:  Catherine L Granger; Lara Edbrooke; Linda Denehy
Journal:  Ann Transl Med       Date:  2018-12

2.  Exercise capacity and cancer-specific quality of life following curative intent treatment of stage I-IIIA lung cancer.

Authors:  Duc Ha; Andrew L Ries; Peter J Mazzone; Scott M Lippman; Mark M Fuster
Journal:  Support Care Cancer       Date:  2018-02-10       Impact factor: 3.603

Review 3.  The Utility of Exercise Testing in Patients with Lung Cancer.

Authors:  Duc Ha; Peter J Mazzone; Andrew L Ries; Atul Malhotra; Mark Fuster
Journal:  J Thorac Oncol       Date:  2016-05-05       Impact factor: 15.609

4.  Bronchial sleeve resection or pneumonectomy for non-small cell lung cancer: a propensity-matched analysis of long-term results, survival and quality of life.

Authors:  Saana E M Andersson; Ville H S Rauma; Eero I Sihvo; Jari V Räsänen; Ilkka K Ilonen; Jarmo A Salo
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

5.  Survival in the elderly after pneumonectomy for early-stage non-small cell lung cancer: a comparison with nonoperative management.

Authors:  Paul J Speicher; Asvin M Ganapathi; Brian R Englum; Mark W Onaitis; Thomas A D'Amico; Mark F Berry
Journal:  J Am Coll Surg       Date:  2013-12-12       Impact factor: 6.113

Review 6.  The clinical use of regenerative therapy in COPD.

Authors:  Roberto Lipsi; Paola Rogliani; Luigino Calzetta; Andrea Segreti; Mario Cazzola
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-12-12

7.  Unilateral absent pulmonary artery in an adult - A diagnostic and therapeutic challenge.

Authors:  Faheem Seedat; Ismail S Kalla; Charles Feldman
Journal:  Respir Med Case Rep       Date:  2017-09-14

8.  Pneumonectomy - permanent injury or still effective method of treatment? Early and long-term results and quality of life after pneumonectomy due to non-small cell lung cancer.

Authors:  Piotr J Skrzypczak; Magdalena Roszak; Mariusz Kasprzyk; Anna Kopczyńska; Piotr Gabryel; Wojciech Dyszkiewicz
Journal:  Kardiochir Torakochirurgia Pol       Date:  2019-04-04

9.  Evaluation of left and right ventricular myocardial function after lung resection using speckle tracking echocardiography.

Authors:  Zhenhua Wang; Jianjun Yuan; Wen Chu; Yuhong Kou; Xijun Zhang
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.